Moreover, considering the promising suppression of NSCLC with CDK9 inhibitors seen in EGFR-TKI resistant NSCLC [79], further investigation into their potential in ALK+ NSCLC is warranted. Here, CDK9 is linked to non-small cell lung carcinoma.